Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation.
暂无分享,去创建一个
Hagen von Briesen | Andreas Zimmer | Dirk Lochmann | A. Zimmer | A. Bouazzaoui | H. von Briesen | D. Lochmann | J. Kreuter | Jörg Kreuter | Norbert Dinauer | Ilhan Demirhan | Abdellatif Bouazzaoui | Angelika Chandra | N. Dinauer | A. Chandra | I. Demirhan
[1] D. Conklin,et al. Regulation of the angiotensin type-1 receptor by antisense oligonucleotides occurs through an RNase H-type mechanism. , 1999, Brain research. Molecular brain research.
[2] C. F. Bennett,et al. Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.
[3] R. Balhorn,et al. Condensation of DNA by Spermatid Basic Nuclear Proteins* , 2002, The Journal of Biological Chemistry.
[4] G. Amidon,et al. Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential , 2003, Gene Therapy.
[5] M. Hentze,et al. Target-specific arrest of mRNA translation by antisense 2'-O-alkyloligoribonucleotides. , 1994, Nucleic acids research.
[6] A. Gewirtz,et al. Nucleic acid therapeutics: a work in progress. , 2002, Current opinion in investigational drugs.
[7] C. Leonetti,et al. Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. , 1999, Antisense & nucleic acid drug development.
[8] K. C. Ting,et al. Microparticles of poly(dl-lactic-co-glycolic acid)/poly(ethylene glycol) blends for controlled drug delivery , 1997 .
[9] E. Lesnik,et al. Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. , 1999, Antisense & nucleic acid drug development.
[10] R. Pecora. Dynamic Light Scattering , 1985 .
[11] M. Wainberg,et al. Antiviral activity and protection of cells against human immunodeficiency virus type-1 using an antisense oligodeoxyribonucleotide phosphorothioate complementary to the 5'-LTR region of the viral genome. , 1995, Gene.
[12] Robert Gurny,et al. Inhibition of HIV-1 in Cell Culture by Oligonucleotide-Loaded Nanoparticles , 2001, Pharmaceutical Research.
[13] R. Stahel,et al. Antisense oligonucleotides for cancer therapy-an overview. , 2003, Lung cancer.
[14] T. Thomas,et al. DNA nanoparticles and development of DNA delivery vehicles for gene therapy. , 2002, Biochemistry.
[15] Jean-Philippe Richard,et al. Cellular uptake and intracellular fate of antisense oligonucleotides. , 2003, Current opinion in molecular therapeutics.
[16] V. Vlassov,et al. Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides , 2005, Virus Genes.
[17] R. Kozłowski,et al. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. , 1993, Journal of immunological methods.
[18] E. Wickstrom,et al. alpha-Oligodeoxynucleotide stability in serum, subcellular extracts and culture media. , 1986, Journal of biochemical and biophysical methods.
[19] K. G. Wagner,et al. Cooperative binding of fluorescein-labeled clupeine by DNA , 1976, Nucleic Acids Res..
[20] B. Berne,et al. Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics , 1976 .
[21] Particle sizing by photon correlation spectroscopy. Part III: Mono and bimodal distributions and data analysis , 1992 .
[22] W. J. Irwin,et al. Biodegradable poly(L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides , 1995 .
[23] T. Antony,et al. Laser light scattering immunoassay: an improved data analysis by CONTIN method. , 1998, Journal of biochemical and biophysical methods.
[24] R. Pecora,et al. Dynamic Light Scattering Measurement of Nanometer Particles in Liquids , 2000 .
[25] R. Juliano,et al. Cellular uptake and intracellular fate of antisense oligonucleotides. , 1992, Trends in cell biology.
[26] J. Kreuter,et al. Nanoparticulate systems for brain delivery of drugs. , 2001 .
[27] S. Akhtar,et al. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres , 1997 .
[28] C. Königs,et al. Analysis of cellular factors influencing the replication of human immunodeficiency virus type I in human macrophages derived from blood of different healthy donors. , 2001, Virology.
[29] J. H. Li,et al. Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity. , 1996, Biochemical and molecular medicine.
[30] R. Byrn,et al. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. , 1997, AIDS research and human retroviruses.
[31] A. Zimmer,et al. Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles. , 2001, Biochimica et biophysica acta.
[32] L. Good,et al. Translation repression by antisense sequences , 2003, Cellular and Molecular Life Sciences CMLS.
[33] K S Thompson,et al. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems. , 2000, Journal of drug targeting.
[34] W. J. Irwin,et al. A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. , 1996, Molecular pharmacology.